Amgen Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (88)

Latest Posts

About This Stock More About This Stock
Forget Teva, Buy These 5 Drug Stocks Instead
Article By: Arpita Dutt
Monday, October 9, 2017 1:43 PM EDT
While Teva deals with these challenges, I have selected five drug companies that look well-positioned.
In this article: PFE, LGND, AMGN, CELG, VRTX Also: MYL, TEVA
Read
Week In Review: Another Billion Dollar Week For China Life Science Deals
Article By: ChinaBio® Today
Saturday, September 30, 2017 5:55 PM EDT
Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen -- possibly Alvogen's US operations -- according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion.
In this article: NVO, SNY, SVA, AMGN, GILD, ZLAB, TSRO
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich
Friday, September 29, 2017 7:25 PM EDT
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
Astrazeneca, Amgen Phase IIb Trial Of Tezepelumab Met Primary Endpoint
Article By: The Fly
Thursday, September 7, 2017 8:20 AM EDT
AstraZeneca and Amgen announced results from the Pathway Phase IIb trial of tezepelumab that they say "showed a significant reduction" in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma.
In this article: AZN, AMGN
Read
Biopharmaceuticals Portfolio In A Biotech Bull Market
Article By: Rod Raynovich
Tuesday, September 5, 2017 11:08 PM EDT
Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4.
In this article: BMY, RHHBY, IBB, QQQ, AMGN, BIIB, GILD, XBI, ABBV, KITE, BLUE, FMI
Read

PARTNER HEADLINES

Latest Tweets for $AMGN

No tweets yet!

$AMGN

July 2017 Stock Considerations
Dick Kaplan 7/3/2017 3:14:44 AM

I read that #Repatha sales for this quarter are down significantly so be careful with $AMGN.

1 to 1 of 1 comments